Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.

Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, our company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.

Our company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of our innovative and proprietary technology platform. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further our mission to transform the lives of patients and deliver on the promise of CRISPR technologies.

Selected Investors

Validating partnerships with sophisticated collaborators accelerate our evolution

  • Regeneron

    • Over a decade of investment and experience in genetic medicines through Regeneron Genetics Center
    • Company that has developed and commercialized many therapies for serious diseases
    • Complementary AAV technology

    Key Terms:

    • Multiple in-vivo indications
    • $100M Upfront and Equity investment
    • $370 million per target in development, regulatory and commercial milestone payments
    • Royalty rates ranging from single digits to mid teens on future net sales
    • Right to opt-in to co-funding and sharing profits on a majority of collaboration programs

  • Vertex

    • First approved CRISPR based therapy
    • High-science company with successful track record in developing therapies for highly complex diseases
    • Complementary AAV delivery technology (Affinia)

    Key Terms:

    • Two in vivo indications
    • Upfront payments and investments of $40 million
    • Up to $650 million in potential future payments
    • Tiered royalties on net sales

Leadership

Our leadership team has a legacy of cutting edge scientific research and business achievement.

Board Members

  • Trevor Martin, Ph. D.

    Co-founder, Chief Executive Officer

  • Janice Chen, Ph. D.

    Co-founder, Chief Scientific Officer & President, Research

  • Lucas Harrington, Ph. D.

    Co-founder

  • Jeff Huber

    Chair | Triatomic Capital

  • Amrit Nagpal

    Redmile Group

  • Min Cui, Ph. D.

    Decheng Capital

  • Ursheet Parikh

    Mayfield

  • Maneesh Jain, Ph. D.

    CEO/Co-founder Mirvie

  • Bob Brown, Ph.D.

    Former EVP of R&D and President, Dicerna

Scientific Advisory Board

  • Jennifer Doudna, Ph. D.

    Chair | Co-Founder | Professor, UC Berkeley

  • Charles Albright, Ph. D.

    CSO, Affinia Therapeutics

Selected Awards

California Life Sciences Pantheon Award for Emerging InnovationLearn More EY Entrepreneur of the Year Regional Winner and National Finalist 2021Learn More In Vivo’s 2024 Rising LeadersLearn More Endpoints 11 Biopharma's Most Promising Startups in 2022Learn More Fast Company Next Big Things in Tech 2022Learn More BioSpace's 2023 Best Places to WorkLearn More MIT Technology Review 35 Innovators Under 35Learn More Endpoints Top 20 Women in BiopharmaLearn More Forbes "30 Under 30"Learn More

Contact Us

Email: info@mammothbiosci.com
Partnerships: partner@mammothbiosci.com
Phone: +1-650-294-8583

Mammoth Biosciences, Inc.
1000 Marina Blvd.
Brisbane, CA 94005

For press inquiries please contact media@mammothbiosci.com

Trevor Martin

Co-founder, Chief Executive Officer

Dr. Trevor Martin is the co-founder and CEO of Mammoth Biosciences, where we are harnessing the diversity of nature to power the next generation of curative CRISPR therapies for genetic diseases, as well as improving human health and wellbeing. Through our AI enabled discovery and development of novel CRISPR systems, including from co-founder and Nobel Prize winner Jennifer Doudna's lab, we are enabling the full potential of our platform to read and write the code of life.

Trevor earned his BA from Princeton University and his Ph.D. from Stanford. His scientific work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is an EY Entrepreneur of the Year 2021. Mammoth has raised over $465M from leading investors in the US and internationally.

Janice Chen

Co-founder, Chief Scientific Officer & President, Research

Janice Chen is the co-founder, CSO and President of Research at Mammoth Biosciences, where we are harnessing the diversity of nature to develop in vivo gene editing therapies. Through our discovery of novel CRISPR systems, we are enabling the full potential of our platform to read and write the code of life.

Janice received her PhD from the lab of Nobel Laureate Jennifer Doudna at University of California, Berkeley, where she investigated mechanisms of CRISPR-Cas proteins and is an inventor of several CRISPR-based technologies. Janice's work has been recognized by several organizations, including Forbes 30 Under 30 in Healthcare, Endpoints Top 20 Women in Biopharma, and MIT Technology Review 35 Innovators Under 35.

Jennifer Doudna

Co-founder, Chair of Scientific Advisory Board

As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by discovering a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria, known as CRISPR. Doudna is an Investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. She is also a Foreign Member of the Royal Society and has received many other honors including, the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award and the Japan Prize.

Elaine Sun

Chief Financial Officer and Chief Operating Officer

Elaine joined Mammoth from Halozyme Therapeutics, where she was SVP and Chief Financial Officer of a profitable, commercial-stage biotechnology company. Prior to Halozyme, she served as Chief Financial Officer and Chief Strategy Officer at SutroVax (now Vaxcyte), a developer of next-generation pneumococcal conjugate vaccines. Elaine brings with her 25 years of experience in the life sciences industry, including building and growing both private and public companies. While at SutroVax, she provided strategic, operational and financial leadership for a rapidly growing organization, including establishing innovative supply partnership agreements. Previously, Elaine served as Managing Director and Head of West Coast Healthcare at Evercore Partners and Managing Director at Merrill Lynch. Over her investment banking career, she led and played key roles in a broad range of pharmaceutical, biotechnology and medical device M&A and financing transactions valued in excess of $50 billion. She currently serves on the Board of Directors of Dynavax Technologies and previously served on the Board of Directors of Cirius Therapeutics. Elaine received her BA from Wellesley College and MBA from Harvard Business School.

Gabor Veres

SVP, Translational Sciences

Aruna Perera

VP, Technical Operations

Sandeep Soni

VP, Clinical Development

Siang Chin

General Counsel and Head of Alliance Management

Siang has an extensive career guiding legal strategy at leading biotechnology, life sciences, and medtech companies — successfully executing transformational transactions and navigating complex regulatory and intellectual property matters. Siang was previously General Counsel of Affymetrix, Inc., where she was part of an executive team that drove growth, profitability, and the company’s acquisition by Thermo Fisher Scientific in 2016. In her most recent position as Vice President and Assistant General Counsel at Intuitive Surgical, she led and grew the corporate, commercial, and compliance legal functions and was instrumental in executing the company’s strategic acquisitions, joint ventures, and key collaborations. Siang received her Bachelor of Laws from King’s College London and her Master of Laws from Georgetown University.